|
Discussion of Assessing Heterogeneity of Treatment Effect, Estimating Patient-Specific Efficacy, and Studying Variation in Odds ratios, Risk Ratios, and Risk Differences
|
|
37
|
13570
|
August 23, 2026
|
|
Problems with NNT
|
|
37
|
40307
|
August 10, 2025
|
|
Non-collapsibility of standardized rate
|
|
14
|
1399
|
August 31, 2024
|
|
Effect sizes for power and evidence for effectiveness
|
|
24
|
2904
|
July 24, 2024
|
|
Use of percentage change in clinical trials
|
|
17
|
9969
|
July 22, 2024
|
|
Is it legitimate to perform statistical test on test statistics such as t-values or z-scores?
|
|
5
|
4993
|
January 26, 2023
|
|
Clarification on risk magnification
|
|
7
|
4103
|
May 9, 2022
|
|
Calculating years of life lost due to COVID-19
|
|
3
|
4561
|
June 10, 2021
|
|
Calculating SMD from geometric mean titers
|
|
2
|
6361
|
May 26, 2021
|
|
Odds ratios seem to be collapsible?
|
|
17
|
8830
|
February 25, 2021
|
|
When to use absolute vs relative effect measures
|
|
13
|
45383
|
February 8, 2020
|
|
Which SD to use when calculating standardised mean differences?
|
|
1
|
4252
|
October 2, 2019
|
|
Inequality of Variances in an RCT
|
|
12
|
9297
|
December 27, 2018
|
|
Absolute risk measures from count models
|
|
6
|
8318
|
October 24, 2018
|